Adaptimmune Therapeutics plc (473A) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Adaptimmune Therapeutics plc (473A) has a cash flow conversion efficiency ratio of 0.490x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-34.78 Million ≈ $-40.66 Million USD) by net assets (€-70.96 Million ≈ $-82.96 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Adaptimmune Therapeutics plc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Adaptimmune Therapeutics plc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Adaptimmune Therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Adaptimmune Therapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adaptimmune Therapeutics plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Very Good Tour Co. Ltd
KQ:094850
|
-0.017x |
|
Upsales Technology AB
ST:UPSALE
|
0.461x |
|
Oceanpal Inc
NASDAQ:OP
|
-0.007x |
|
Sportshero Ltd
AU:SHO
|
1.185x |
|
Modernform Group Public Company Limited
BK:MODERN
|
0.018x |
|
AXIOS Sustainable Growth
NYSE:AXAC
|
-0.003x |
|
Abocom Systems Inc
TW:2444
|
-0.115x |
|
Sand Nisko Capital Bhd
KLSE:7943
|
-0.028x |
Annual Cash Flow Conversion Efficiency for Adaptimmune Therapeutics plc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Adaptimmune Therapeutics plc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see 473A market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €11.85 Million ≈ $13.85 Million |
€-73.21 Million ≈ $-85.59 Million |
-6.178x | -73.28% |
| 2023-12-31 | €39.51 Million ≈ $46.19 Million |
€-140.88 Million ≈ $-164.70 Million |
-3.565x | -105.92% |
| 2022-12-31 | €81.88 Million ≈ $95.72 Million |
€-141.77 Million ≈ $-165.74 Million |
-1.731x | -3423.82% |
| 2021-12-31 | €205.96 Million ≈ $240.79 Million |
€10.73 Million ≈ $12.54 Million |
0.052x | +133.17% |
| 2020-12-31 | €341.23 Million ≈ $398.93 Million |
€-53.59 Million ≈ $-62.65 Million |
-0.157x | +82.74% |
| 2019-12-31 | €123.64 Million ≈ $144.55 Million |
€-112.51 Million ≈ $-131.53 Million |
-0.910x | -115.21% |
| 2018-12-31 | €246.88 Million ≈ $288.63 Million |
€-104.39 Million ≈ $-122.04 Million |
-0.423x | -58.01% |
| 2017-12-31 | €202.98 Million ≈ $237.31 Million |
€-54.31 Million ≈ $-63.50 Million |
-0.268x | +7.70% |
| 2016-12-31 | €166.14 Million ≈ $194.24 Million |
€-48.17 Million ≈ $-56.31 Million |
-0.290x | -- |
About Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatmen… Read more